New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

@article{Beard2016NewPA,
  title={New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?},
  author={Emma Beard and Lion Shahab and Damian M. Cummings and Susan Michie and Robert J West},
  journal={CNS Drugs},
  year={2016},
  volume={30},
  pages={951-983}
}
A wide range of support is available to help smokers to quit and to aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. [...] Key Method Six ‘ESCUSE’ criteria—relative efficacy, relative safety, relative cost, relative use (overall impact of effective medication use), relative scope (ability to serve new groups of patients) and relative ease of use—are used. Many of these products are in the early stages of clinical…Expand
Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking
TLDR
This article reviewed existing and emerging smoking cessation pharmacotherapies, with a special emphasis on the most promising agents that are currently being investigated, including NRT, bupropion, and varenicline. Expand
Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation
TLDR
Based on current evidence, CB1 receptor neutral antagonists and fatty acid amide hydrolase inhibitors demonstrate positive effects in studies assessing several addiction-related factors and suggest they offer the greatest promise as novel cessation and anti-relapse agents. Expand
Tobacco use disorder and treatment: new challenges and opportunities
TLDR
There is still “low-hanging fruit” to be gained in educating on the proper use of nicotine replacement medications, how smoking cessation can change blood levels of specific medications and caffeine, and how to connect with quitlines and mobile technology options. Expand
Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials
TLDR
A literature review revealed that bupropion may be appropriate for patients interested in reducing smoking who dislike, or who have failed, nicotine-replacement therapy (NRT). Expand
Medicalisation, smoking and e-cigarettes: evidence and implications
TLDR
It is argued that the medicalisation of smoking will have limited impact due to the emphasis on population-based interventions in tobacco control, the ambiguous place of nicotine among other drugs and the modest efficacy of current pharmacotherapies. Expand
The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.
TLDR
If cytisine is as effective as varenicline, its lower cost and natural plant-based composition may make it an acceptable and affordable smoking cessation medication that could save millions of lives world-wide. Expand
E-cigarettes in patients with COPD: current perspectives
TLDR
The use of ECs in vulnerable groups and in patients with challenges to abstain or multiple relapses to this habit may be promising, and little is known about health consequences of EC use among COPD smokers and whether their regular use has any effects on subjective and objective COPD outcomes. Expand
Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders
TLDR
This review highlights the epidemiology, contributing factors, and evidence-base for intervening upon tobacco use in those with mental illness and addictive disorders, and summarizes novel, emerging approaches to mitigate the harms of cigarette smoking. Expand
Managing nicotine without smoke to save lives now: Evidence for harm minimization.
TLDR
Saving more lives now is an attainable and pragmatic way to call for alignment of all stakeholders and factions within traditional tobacco control rather than perpetuate the unrealized and unrealizable perfection of nicotine prohibition. Expand
Psychological Aspects of Tobacco Control
TLDR
Interventions which address physiological and behavioural addiction inherent in tobacco product use, create social pressure to stop, or increase the cost of tobacco products are most likely to be effective at encouraging quit attempts. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 433 REFERENCES
Non-Nicotine Pharmacotherapy for Smoking Cessation
TLDR
A stepped care approach for the selection of pharmacotherapies is presented in this review, hoping that ultimately medications can be matched with the individual characteristics of a smoker, and that smoking cessation could be facilitated in most smokers. Expand
Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
TLDR
The outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment, and the outcome for harms is the incidence of serious adverse events associated with each of the treatments. Expand
Nicotine replacement therapy for smoking cessation.
TLDR
The effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the smoker, and the combination of bupropion and nicotine patch was significantly more effective than nicotine patch alone. Expand
Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal
TLDR
A range of novel pharmacological approaches for the treatment of tobacco dependence and/or withdrawal are focused on, including oral and pulmonary nicotine delivery and the following non-nicotinic medications: antidepressants, an α4β2 nicotine partial agonist, anα2-noradrenergic agonists, cytochrome P450 (CYP) 2A6 inhibitors, opioid antagonists and GABAergic medications. Expand
Nicotine replacement therapy for smoking cessation.
TLDR
All of the commercially available forms of NRT (nicotine gum, transdermal patch, the nicotine nasal spray, nicotine inhaler and nicotine sublingual tablets) are effective as part of a strategy to promote smoking cessation and they increase quit rates approximately 1.5 to 2 fold regardless of setting. Expand
Antidepressants for smoking cessation.
TLDR
There is insufficient evidence that adding bupropion or nortriptyline to nicotine replacement therapy provides an additional long-term benefit, and the antidepressants buPropion and nortriptYline appear to be equally effective and of similar efficacy to Nicotine replacement therapy. Expand
Nicotine Vaccines to Assist with Smoking Cessation Current Status of Research
Tobacco smoking causes cardiovascular, respiratory and malignant disease, and stopping smoking is among the key medical interventions to lower the worldwide burden of these disorders. However, theExpand
Anxiolytics and antidepressants for smoking cessation.
TLDR
There is little evidence that anxiolytics aid smoking cessation, and it is not clear whether these effects are specific for individual drugs, or a class effect. Expand
Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success?
  • E. Gilpin, K. Messer, J. Pierce
  • Medicine
  • Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2006
TLDR
The California population experience supports the policy that programs subsidizing pharmaceutical aids to help smokers quit (particularly bupropion, if appropriate) should target highly motivated smokers who have already taken a behavioral action, such as implementing a smoke-free home. Expand
Nicotine Vaccines to Assist with Smoking Cessation
TLDR
The failure of encouraging preclinical data to completely translate to clinical studies may be partially explained by shortcomings of animal models of addiction and an incomplete understanding of the complex physiological and behavioural processes contributing to tobacco addiction. Expand
...
1
2
3
4
5
...